Articles dans des revues avec comité de lecture (100)
  1. 37. Soumoy, L., Kindt, N., Ghanem, G. E., Saussez, S., & Journé, F. (2019). Role of macrophage migration inhibitory factor (Mif) in melanoma. Cancers (Basel), 11(4), 529. doi:10.3390/cancers11040529
  2. 38. Bobin, F., Journé, F., & Lechien, J. (2019). Saliva pepsin level of laryngopharyngeal reflux patients is not correlated with reflux episodes. The Laryngoscope. doi:10.1002/lary.28260
  3. 39. Kindt, N., Descamps, G., Lechien, J., Remmelink, M., Colet, J.-M., Wattiez, R., Berchem, G., Journé, F., & Saussez, S. (2019). Involvement of HPV infection in the release of macrophage migration inhibitory factor in head and neck squamous cell carcinoma. Journal of Clinical Medicine, 8(1), 75. doi:10.3390/jcm8010075
  4. 40. Krayem, M., Najem, A., Journé, F., Morandini, R., Sales, F., Awada, A., & Ghanem, G. E. (2018). Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget, 9(61), 31888-31903. doi:10.18632/oncotarget.25879
  5. 41. Seminerio, I., Kindt, N., Descamps, G., Bellier, J., Lechien, J., Mat, Q., Pottier, C., Journé, F., & Saussez, S. (2018). High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus. Oncotarget, 9(13), 11046-11059. doi:10.18632/oncotarget.24306
  6. 42. Perdrix, A., Najem, A., Saussez, S., Awada, A., Journé, F., Ghanem, G. E., & Krayem, M. (2017). PRIMA-1 and PRIMA-1Met (APR-246): From mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies. Cancers (Basel), 9(12), 172. doi:10.3390/cancers9120172
  7. 43. Lechien, J., Nassri, A., Kindt, N., Brown, D. N., Journé, F., & Saussez, S. (2017). Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic review. Head & neck, 39(12), 2573-2584. doi:10.1002/hed.24939
  8. 44. Kindt, N., Journé, F., Ghanem, G. E., & Saussez, S. (2017). Galectins and carcinogenesis: Their role in head and neck carcinomas and thyroid carcinomas. International journal of molecular sciences, 18(12), 2745. doi:10.3390/ijms18122745
  9. 45. Najem, A., Krayem, M., Perdrix, A., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2017). New drug combination strategies in melanoma: Current status and future directions. Anticancer research, 37(11), 5941-5953. doi:10.21873/anticanres.12041
  10. 46. Gilot, D., Migault, M., Bachelot, L., Journé, F., Rogiers, A., Donnou-Fournet, E., Mogha, A., Mouchet, N., Pinel-Marie, M. L., Mari, B., Montier, T., Correia, S., Gautron, A., Rambow, F., El Hajj, P., Ben Jouira, R., Tartare-Deckert, S., Marine, J.-C., Felden, B., Ghanem, G. E., & Galibert, M. D. (2017). A non-coding function of TYRP1 mRNA promotes melanoma growth. Nature cell biology, 19(11), 1348-1357. doi:10.1038/ncb3623
  11. 47. Zhang, Y., Guo, J., Yang, W., Goncalves, C., Rzymski, T., Dreas, A., Zyłkiewicz, E., Mikulski, M., Brzózka, K., Golas, A., Kong, Y., Ma, M., Huang, F., Huor, B., Guo, Q., Da Silva, S. D., Rivera-Torres, J., Cai, Y., Topisirovic, I., Su, J., Bijian, K., Alaoui-Jamali, M. A., Huang, S., Journé, F., Ghanem, G. E., Miller, W. W., & Del Rincón, S. S. (2017). MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. The Journal of clinical investigation, 127(11), 4179-4192. doi:10.1172/JCI91258
  12. 48. Najem, A., Krayem, M., Sales, F., Hussein, N., Badran, B., Robert, C., Awada, A., Journé, F., & Ghanem, G. E. (2017). P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European journal of cancer, 83, 154-165. doi:10.1016/j.ejca.2017.06.033
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 Suivant >>